| Original language | English |
|---|---|
| Pages (from-to) | 319-322 |
| Number of pages | 4 |
| Journal | European Urology |
| Volume | 81 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2022 |
Bibliographical note
Funding Information:Conflicts of interest: Malcolm D. Mason is a company consultant for Ellipses Pharma and Oncotherics, and has received payments for membership of data mintoring committees for Endocyte and for Clovis. Theodorus van der Kwast has received research support from Google Inc. Nicolas Mottet is a company consultant for Janssen, GE, BMS, Sanofi, and Astellas; has received speaker honoraria from Astellas, Pierre Fabre, Steba, Janssen, and Ferring; and has received fellowships and travel grants from Astellas, Ipsen, Sanofi, Janssen, and Roche. Olivier Rouvière has received a speaker honorarium from EDAP-TMS and travel grants and research support from Philips, and has participated in clinical trials run by EDAP-TMS and Vermon. Erik Briers has received grants and research support from Ipsen, the European Association of Urology, and Bayer; is an ex officio board member for Europa UOMO; is an ethics committee and advisory group member for REQUITE; is a patient advisory board member for PAGMI; and is a member of SCA and EMA PCWP. Philip Cornford is a company consultant for Astellas, Ipsen, and Ferring; has received company speaker honoraria from Astellas, Janssen, Ipsen, and Pfizer; has participated in trials run by Ferring; and has received fellowships and travel grants from Astellas and Janssen. Maria De Santis is a company consultant for Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai Inc., ESSA, Ferring, GSK, Incyte, Ipsen, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, Teva, OncoGenex, and Sandoz; receives speaker honoraria from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ferring, GSK, Ipsen, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, Synthon, and Takeda; participates in trials run by the Technical University Munich, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai Inc, Ferring, GSK, Ipsen, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SOTIO, and Cancer Research UK; and as a member of the EORTC GU group participates in various trials. She has received research grants from Pierre Fabre Oncologie, and travel grants from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreaon, Ferring, GSK, Ipsen, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, and Teva/OncoGenex. Silke Gillessen is a company consultant for AAA International, Astellas Pharma, Bayer, Bristol-Myers Squibb, Clovis, CureVac, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxIVAX SA, Orion, Roche, Sanofi Aventis Group, Nectar, and ProteoMediX; has received speaker honoraria from Janssen and Novartis; and participates in multiple trials sponsored by different companies. Shane O’Hanlon has received travel grants from SIOG and ESMO and research support from Sláintecare. Jeremy P. Grummet has received a speaker honorarium from Mundipharma, a travel grant from Astellas, and a research grant from Cancer Australia; and is the owner of MRI PRO Pty Ltd., an online training platform. Ann M. Henry is a company consultant for Nucletron-Elektra; participates in trials run by Cancer Research UK and the National Institute of Health Research (UK); has received travel grants from the Medical Research Council, the National Institute of Health Research (UK), and Cancer Research UK; and has received research grants from Cancer Research UK and the Sir John Fisher Foundation. Thomas B.L. Lam is a company consultant for and has received company speaker honoraria and travel grants from Pfizer, GSK, Astellas, IPSEN, and Consilient Health. Guillaume Ploussard is a company consultant for Janssen, Takeda, Ferring, Ipsen, Astellas, and Koelis, has received company speaker honoraria from Janssen, Takeda, Ferring, Ipsen, Astellas, and Bayer, and has received research support from Ferring. Henk G. van der Poel is a company consultant for Intuitive Surgical; has participated in trials for Astellas and Steba Biotech; and has received grant and research support from Astellas. Derya Tilki has received speaker honoraria from Astellas and a travel grant from Janssen. Thomas Wiegel is an advisory board member for IPSEN; receives company speaker honoraria from IPSEN and Hexal; is a member of the Janssen steering committee; and has participated in the ATLAS/AUO trial. Thomas Van den Broeck, Ivo G. Schoots, Michael Lardas, Matthew Liew, Giorgio Gandaglia, Nicola Fossati, Marcus Cumberbatch, Roderick C.N. van den Bergh, Daniela E. Oprea-Lager, Lisa Moris, Andrea Farolfi, Peter-Paul M. Willemse, and Nikolaos Grivas have nothing to disclose.
